i will provide details of one patient which was diagnosed as GPA ONE BY ONE register the details as we need to make a clinical case presentation in RHEUMIGNITE in which presenter would be DR AYUSHI AGRAWAL (2ND YR GENERAL MEDICINE RESIDENT)
| Parameter | Details |
|---|---|
| Name | Mr. Ashifbhai Ganibhai Kureshi |
| MRN | 26000422128 |
| IP No. | IP2603007540 |
| Age / Sex | 29 years / Male |
| Occupation | Auto Driver |
| Addiction | Tobacco chewer (3–4 masalas/day; stopped ~1 month prior) |
| Diet | Mixed |
| Marital Status | Married, 1 child |
| Education | 10th standard |
| Admission Date | 21-03-2026 |
| Discharge Date | 03-04-2026 |
| Informant | Ganibhai (Patient's Father) |
| Vital | Value |
|---|---|
| Temperature | Normal |
| Pulse Rate | 94/min |
| Blood Pressure | 120/70 mmHg |
| Respiratory Rate | 20/min |
| SpO₂ | 98% on Room Air |
| RBS | 141 mg/dL |
| RS | B/L air entry present, crepts + |
| CVS | S1 S2 + |
| CNS | COFVC |
| Per Abdomen | Soft |
| Pedal Edema | No |
| Clubbing | No |
| Date | Diagnosis / Key Event |
|---|---|
| 21/03/26 | Admitted under Emergency/Pulmonology — LRTI; transferred to ICU |
| 22/03/26 | S/B ENT, Ortho, Cardiology; C-ANCA sent |
| 23/03/26 | S/B Psychiatry (anxiety due to GMC) |
| 24/03/26 | Vasculitis profile sent; S/B Gastromedicine (transaminitis) |
| 26/03/26 | CECT Thorax done — nodular infiltrates + partial thrombosis of left posterobasal segmental artery; C-ANCA collected |
| 27/03/26 | Rheumatology referral — KDN for C-ANCA positivity and pulse steroid therapy |
| 28/03/26 | CT PNS done; ENT, Nephrology, Urology consulted for ?GPA |
| 30/03/26 | Rheumatology impression: GPA likely — PR-3 by ELISA ordered; Inj MPS 750 mg IV OD x3–5 days started; Inj Endoxan 900 mg planned |
| 31/03/26 | Inj Endoxan (Cyclophosphamide) 900 mg IV given |
| 02–03/04/26 | Tab Omnacortil (Prednisolone) 40 mg started; condition improved |
| 03/04/26 | Discharged — Status: Recovered; Care: Rheumatology |
| Test | Result |
|---|---|
| C-ANCA | Positive (21/03/2026) |
| PR-3 by ELISA | Ordered (result awaited at discharge) |
| P-ANCA | Sent |
| ANA by IF | Sent |
| Coombs Direct/Indirect | Ordered (30/03/26) |
| Anti-phospholipid | Ordered |
| Date | Hb | WBC | Platelets | Neutrophils | ESR |
|---|---|---|---|---|---|
| 21/03/26 | 9.9 (L) | 12.24 (H) | 684 (H) | 82% (H) | 85 (H) |
| 22/03/26 | 10.3 (L) | 17.46 (H) | 795 (H) | 87% (H) | — |
| 23/03/26 | 9.6 (L) | 14.08 (H) | 858 (H) | 86% (H) | — |
| 24/03/26 | 9.5 (L) | 15.45 (H) | 675 (H) | 84% (H) | — |
| 29/03/26 | 8.8 (L) | 14.71 (H) | 640 (H) | 87% (H) | 85 (H) |
| 15/04/26 (OPD) | 11.3 (L) | 12.15 (H) | 776 (H) | 79% | 38 (H) |
| Parameter | Value |
|---|---|
| Creatinine | 0.58–0.76 (Low-normal; preservation of renal function) |
| Blood Urea | Normal range |
| Electrolytes | Mostly within range; one instance K+ 5.64 (H) |
| TIBC | 213 (L) — suggesting chronic disease |
| Parameter | Value |
|---|---|
| SGOT | 83 (H) → trended down |
| SGPT | 103–140 (H) → 88 → 102 |
| ALP | 214 (H) → 233 |
| Total Bilirubin | 1.2–2.3 (H) |
| Albumin | 3.5 → 3.2 (low) |
| Test | Value |
|---|---|
| CRP | Elevated (sent multiple times) |
| ESR | 85 mm/1hr (peak) |
| Procalcitonin | 0.25–0.47 (H) — suggesting bacterial co-infection |
| Ferritin | >1650 (markedly elevated) |
| LDH | 254 (H) on 30/03 |
| NT-proBNP | 372 (H) — mildly elevated |
| Test | Result |
|---|---|
| Sputum C/S (22/03/26) | Gram +ve cocci seen |
| Sputum cytology (24/03/26) | NAD |
| Sputum CBNAAT | Sent |
| Blood C/S | Sent |
| Urine C/S | Sent |
| Dengue NS1 | Ordered |
| HEV Ab | Positive (incidental) |
| HAV | Sent |
| Malaria | Negative |
| Specialty | Key Findings / Advice |
|---|---|
| Rheumatology | GPA likely; PR-3 ELISA; Pulse steroids + Cyclophosphamide |
| ENT | DNS, crusting, blood clots; CT PNS advised |
| Nephrology | Renal biopsy discussed (deferred — creatinine preserved) |
| Urology | Renal biopsy opinion — agreed with nephro |
| Cardiology | Echo: normal LV function, no PAH |
| Orthopaedics | Left knee, right ankle: normal X-rays, minimal effusion |
| Gastromedicine | Transaminitis — HEV positive incidentally; monitor LFT |
| Psychiatry | Mixed anxiety-depression secondary to GMC; Tab Sertralline 25 mg HS, Tab Meloset 3 mg HS |
| Physiotherapy | Chest PT throughout admission — diaphragmatic breathing, pursed lip breathing, chest expansion, vibration, ambulation |
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Inj Methylprednisolone (MPS) | 750 mg | IV | OD × 3–5 days (started 30/03/26) |
| Inj Endoxan (Cyclophosphamide) | 900 mg/500 mL NS | IV slowly | Single pulse given 31/03/26 |
| Tab Omnacortil (Prednisolone) | 40 mg | PO | 1-0-0 (started 02/04/26) |
| Drug | Dose | Purpose |
|---|---|---|
| Inj Pantoprazole 40 mg | BD IV | GI protection |
| Tab Shelcal 500 mg | OD PO | Calcium supplementation |
| Cap Uprise D3 60,000 IU | Once weekly (Tuesday) | Vit D supplementation |
| Eye drops CMC-LA | TDS | Dry eye / lubrication |
| Eye drops Moxifloxacin | TDS | Conjunctivitis |
| Ear drops Ciproflox | TDS | Ear |
| Syp Cremaffin 10 mL | TDS PO | Bowel care |
| Glucose powder 2 tsp | TDS | Energy supplementation |
| Xylometazoline nasal drops | TDS | Nasal congestion |
| RBS monitoring | 6-hourly | Steroid-induced hyperglycaemia watch |
| Strict I/O charting | — | Fluid monitoring |
Here it is
What format should the RHEUMIGNITE presentation be in? · What presentation style do you prefer? · Should the CT images you just shared be embedded in the presentation?
mkdir -p /home/daytona/workspace/rheumignite-gpa/assets /home/daytona/workspace/rheumignite-gpa/output && ls /home/daytona/workspace/rheumignite-gpa/
where is the ppt?
ls -la /home/daytona/workspace/ && ls -la /home/daytona/workspace/rheumignite-gpa/ && mkdir -p /home/daytona/workspace/rheumignite-gpa/src /home/daytona/workspace/rheumignite-gpa/output /home/daytona/workspace/rheumignite-gpa/assets
do one thing generate the ppt with whatever information you have and keep it unders 10 slides
ls -la /home/daytona/workspace/ && mkdir -p /home/daytona/workspace/rheumignite-gpa/src /home/daytona/workspace/rheumignite-gpa/output
~/rheumignite-gpa/src/generate_case_presentation.js
const pptxgen = require('pptxgenjs');
const pptx = new pptxgen();
pptx.layout = 'LAYOUT_WIDE'; // 13.333 x 7.5
pptx.author = 'Dr. Ayushi Agrawal';
pptx.company = 'SVP Hospital, Ahmedabad';
pptx.subject = 'RHEUMIGNITE GPA Case';
pptx.title = 'Granulomatosis with Polyangiitis (GPA) - Clinical Case';
pptx.lang = 'en-US';
const C = {
bg: '0B1F2A',
primary: '0E7490',
accent: '06B6D4',
textDark: '0F172A',
textLight: 'E2E8F0',
white: 'FFFFFF',
muted: '475569',
red: 'B91C1C',
green: '166534'
};
function addHeader(slide, title, subtitle='') {
slide.background = { color: C.bg };
slide.addShape(pptx.ShapeType.rect, {
x: 0, y: 0, w: 13.333, h: 0.9,
fill: { color: C.primary },
line: { color: C.primary }
});
slide.addText(title, {
x: 0.4, y: 0.2, w: 9.5, h: 0.45,
fontSize: 22, bold: true, color: C.white, fontFace: 'Calibri'
});
if (subtitle) {
slide.addText(subtitle, {
x: 0.4, y: 0.62, w: 11.8, h: 0.2,
fontSize: 11, color: 'BAE6FD', fontFace: 'Calibri'
});
}
}
function card(slide, x, y, w, h, title) {
slide.addShape(pptx.ShapeType.roundRect, {
x, y, w, h,
rectRadius: 0.08,
fill: { color: C.white },
line: { color: 'CBD5E1', pt: 1 }
});
if (title) {
slide.addText(title, {
x: x + 0.2, y: y + 0.12, w: w - 0.4, h: 0.28,
fontSize: 13, bold: true, color: C.primary
});
}
}
// Slide 1: Title
{
const s = pptx.addSlide();
s.background = { color: C.bg };
s.addShape(pptx.ShapeType.rect, { x: 0, y: 0, w: 13.333, h: 7.5, fill: { color: C.bg }, line: { color: C.bg } });
s.addShape(pptx.ShapeType.roundRect, {
x: 0.7, y: 1.1, w: 11.9, h: 5.2, rectRadius: 0.08,
fill: { color: '0F2D3A' }, line: { color: C.accent, pt: 1.5 }
});
s.addText('RHEUMIGNITE Clinical Case Presentation', {
x: 1.1, y: 1.7, w: 11, h: 0.5, align: 'center',
fontSize: 30, bold: true, color: C.white
});
s.addText('Granulomatosis with Polyangiitis (GPA)\nC-ANCA / PR3 Positive Multisystem Disease', {
x: 1.2, y: 2.45, w: 10.8, h: 1.0, align: 'center',
fontSize: 20, color: 'CFFAFE', bold: true
});
s.addText('Presented by: Dr. Ayushi Agrawal\n2nd Year Resident, Department of General Medicine\nSVP Hospital, Ahmedabad', {
x: 1.2, y: 4.2, w: 10.8, h: 1.2, align: 'center',
fontSize: 16, color: C.textLight
});
}
// Slide 2: Patient profile & timeline
{
const s = pptx.addSlide();
addHeader(s, 'Patient Profile and Clinical Timeline');
card(s, 0.5, 1.2, 5.9, 5.9, 'Patient Details');
s.addText([
{ text: 'Name: Mr. Ashifbhai Ganibhai Kureshi\n', options: { breakLine: true } },
{ text: 'Age/Sex: 29 years / Male\n', options: { breakLine: true } },
{ text: 'Occupation: Auto driver\n', options: { breakLine: true } },
{ text: 'MRN: 26000422128 | IP: IP2603007540\n', options: { breakLine: true } },
{ text: 'Addiction: Tobacco chewing\n', options: { breakLine: true } },
{ text: 'Admission: 21/03/2026\n', options: { breakLine: true } },
{ text: 'Discharge: 03/04/2026', options: {} }
], { x: 0.8, y: 1.7, w: 5.3, h: 2.7, fontSize: 14, color: C.textDark });
card(s, 6.7, 1.2, 6.1, 5.9, 'Illness Timeline');
s.addText([
{ text: '• Private hospital: treated as LRTI\n', options: { breakLine: true } },
{ text: '• Zydus: bilateral consolidation + ?septic arthritis\n', options: { breakLine: true } },
{ text: '• SVP Emergency -> Pulmonology ICU\n', options: { breakLine: true } },
{ text: '• Type 1 respiratory failure at presentation\n', options: { breakLine: true } },
{ text: '• Rheumatology referral after C-ANCA positivity\n', options: { breakLine: true } },
{ text: '• Managed as GPA with vascular involvement', options: {} }
], { x: 7.0, y: 1.7, w: 5.5, h: 3.0, fontSize: 14, color: C.textDark });
s.addShape(pptx.ShapeType.roundRect, {
x: 7.0, y: 5.0, w: 5.5, h: 1.6, rectRadius: 0.05,
fill: { color: 'ECFEFF' }, line: { color: C.accent, pt: 1 }
});
s.addText('Final working diagnosis was reached through clinico-radiological correlation and strongly positive PR3-ANCA.', {
x: 7.2, y: 5.25, w: 5.1, h: 1.1, fontSize: 13, color: '0C4A6E'
});
}
// Slide 3: Presenting complaints
{
const s = pptx.addSlide();
addHeader(s, 'Presenting Complaints and Multisystem Clues');
card(s, 0.7, 1.3, 12.0, 5.7, 'Chief Complaints (duration)');
s.addText([
{ text: '• Dry cough - 20 days\n', options: { breakLine: true } },
{ text: '• Hemoptysis - 15 days\n', options: { breakLine: true } },
{ text: '• Weight loss ~2-3 kg - 10 days\n', options: { breakLine: true } },
{ text: '• Left nasal blockage - 20 days\n', options: { breakLine: true } },
{ text: '• Left knee pain - 2 days\n', options: { breakLine: true } },
{ text: '• Bilateral eye redness - 3 days', options: {} }
], { x: 1.1, y: 1.9, w: 5.8, h: 3.3, fontSize: 18, color: C.textDark });
s.addShape(pptx.ShapeType.line, { x: 6.8, y: 1.8, w: 0, h: 4.8, line: { color: '94A3B8', pt: 1 } });
s.addText('Suggestive systemic pattern', { x: 7.2, y: 1.9, w: 4.8, h: 0.4, fontSize: 16, bold: true, color: C.primary });
s.addText([
{ text: '• ENT involvement: nasal crusting + epistaxis focus\n', options: { breakLine: true } },
{ text: '• Pulmonary involvement: nodules/consolidation + hemoptysis\n', options: { breakLine: true } },
{ text: '• Ocular inflammation: bilateral redness\n', options: { breakLine: true } },
{ text: '• Renal clue: microscopic hematuria + elevated ACR\n', options: { breakLine: true } },
{ text: '• Inflammatory syndrome: ESR 85, thrombocytosis', options: {} }
], { x: 7.2, y: 2.4, w: 5.1, h: 3.2, fontSize: 14, color: C.textDark });
}
// Slide 4: Key investigations
{
const s = pptx.addSlide();
addHeader(s, 'Key Investigations');
card(s, 0.5, 1.2, 4.2, 5.9, 'Inflammatory / Hematology');
s.addText([
{ text: '• Hb nadir: 8.8 g/dL\n', options: { breakLine: true } },
{ text: '• Leukocytosis (neutrophilic)\n', options: { breakLine: true } },
{ text: '• Platelets up to 858 x10⁹/L\n', options: { breakLine: true } },
{ text: '• ESR: 85 mm/hr\n', options: { breakLine: true } },
{ text: '• Ferritin: >1650 ng/mL', options: {} }
], { x: 0.8, y: 1.8, w: 3.6, h: 3.4, fontSize: 13, color: C.textDark });
card(s, 4.9, 1.2, 4.2, 5.9, 'Renal / Urine');
s.addText([
{ text: '• Creatinine preserved\n', options: { breakLine: true } },
{ text: ' (0.58-0.76 mg/dL)\n', options: { breakLine: true } },
{ text: '• Microscopic hematuria\n', options: { breakLine: true } },
{ text: ' (RBC 4-12/HPF)\n', options: { breakLine: true } },
{ text: '• Urine ACR: 40.7 mg/g Cr\n', options: { breakLine: true } },
{ text: '• Renal biopsy deferred', options: {} }
], { x: 5.2, y: 1.8, w: 3.6, h: 3.4, fontSize: 13, color: C.textDark });
card(s, 9.3, 1.2, 3.5, 5.9, 'Serology Highlight');
s.addShape(pptx.ShapeType.roundRect, {
x: 9.7, y: 2.2, w: 2.7, h: 1.9, rectRadius: 0.08,
fill: { color: 'ECFDF5' }, line: { color: '22C55E', pt: 1.2 }
});
s.addText('PR3 (C-ANCA)\n72 IU/mL', {
x: 9.9, y: 2.6, w: 2.3, h: 0.9, align: 'center',
fontSize: 20, bold: true, color: C.green
});
s.addText('Lab cut-off:\n>3 = Positive\n(Strongly positive)', {
x: 9.9, y: 3.55, w: 2.3, h: 1.2, align: 'center',
fontSize: 12, color: C.textDark
});
}
// Slide 5: Imaging findings (without embedded images as files unavailable)
{
const s = pptx.addSlide();
addHeader(s, 'Imaging Findings (CT Thorax and ENT Evaluation)');
card(s, 0.6, 1.2, 6.2, 5.9, 'CT Thorax (CECT findings)');
s.addText([
{ text: '• Bilateral nodular infiltrates\n', options: { breakLine: true } },
{ text: '• Necrotic consolidations\n', options: { breakLine: true } },
{ text: '• Partial thrombosis of left\n', options: { breakLine: true } },
{ text: ' posterobasal segmental artery\n', options: { breakLine: true } },
{ text: '• Radiology supported pulmonary\n', options: { breakLine: true } },
{ text: ' vasculitic process in context', options: {} }
], { x: 1.0, y: 1.9, w: 5.4, h: 3.5, fontSize: 15, color: C.textDark });
card(s, 6.9, 1.2, 5.8, 5.9, 'ENT / PNS');
s.addText([
{ text: '• CT PNS: no frank sinusitis\n', options: { breakLine: true } },
{ text: ' (DNS noted)\n', options: { breakLine: true } },
{ text: '• ENT endoscopy:\n', options: { breakLine: true } },
{ text: ' DNS, crusting, blood clots\n', options: { breakLine: true } },
{ text: ' in left Little’s area\n', options: { breakLine: true } },
{ text: '• ?Right ear cholesteatoma', options: {} }
], { x: 7.3, y: 1.9, w: 5.0, h: 3.5, fontSize: 15, color: C.textDark });
s.addShape(pptx.ShapeType.roundRect, {
x: 0.8, y: 5.8, w: 11.9, h: 0.9, rectRadius: 0.05,
fill: { color: 'FEF2F2' }, line: { color: 'FCA5A5', pt: 1 }
});
s.addText('Note: Shared CT image snapshots can be inserted in final version once files are available in workspace.', {
x: 1.1, y: 6.08, w: 11.3, h: 0.35, fontSize: 12, color: C.red
});
}
// Slide 6: Diagnosis and differential narrowing
{
const s = pptx.addSlide();
addHeader(s, 'Diagnostic Reasoning and Final Diagnosis');
card(s, 0.6, 1.2, 6.3, 5.9, 'Why GPA was favored');
s.addText([
{ text: '• Compatible multisystem phenotype (ENT + lung + eye + renal urinary abnormalities)\n', options: { breakLine: true } },
{ text: '• Hemoptysis with necrotic pulmonary lesions\n', options: { breakLine: true } },
{ text: '• Strong serologic support: C-ANCA/PR3 strongly positive\n', options: { breakLine: true } },
{ text: '• Alternative causes less convincing after workup', options: {} }
], { x: 1.0, y: 1.9, w: 5.6, h: 3.7, fontSize: 14, color: C.textDark });
card(s, 7.1, 1.2, 5.6, 5.9, 'Final Diagnoses');
s.addText([
{ text: '1) Granulomatosis with Polyangiitis\n', options: { breakLine: true } },
{ text: ' (C-ANCA/PR3 positive, multisystem)\n', options: { breakLine: true } },
{ text: '2) Partial thrombosis - left\n', options: { breakLine: true } },
{ text: ' posterobasal segmental artery\n', options: { breakLine: true } },
{ text: '3) Incidental HEV positivity\n', options: { breakLine: true } },
{ text: '4) Mixed anxiety-depression', options: {} }
], { x: 7.5, y: 1.9, w: 4.9, h: 3.8, fontSize: 14, color: C.textDark });
}
// Slide 7: Treatment and hospital course
{
const s = pptx.addSlide();
addHeader(s, 'Treatment Strategy and In-Hospital Course');
card(s, 0.6, 1.2, 6.2, 5.9, 'Immunosuppressive Therapy');
s.addText([
{ text: '• Pulse methylprednisolone\n', options: { breakLine: true } },
{ text: ' 750 mg IV OD for 3-5 days\n', options: { breakLine: true } },
{ text: '• Cyclophosphamide 900 mg IV\n', options: { breakLine: true } },
{ text: ' single pulse (31/03/2026)\n', options: { breakLine: true } },
{ text: '• Discharge steroid:\n', options: { breakLine: true } },
{ text: ' Prednisolone 40 mg OD', options: {} }
], { x: 1.0, y: 1.9, w: 5.4, h: 3.8, fontSize: 14, color: C.textDark });
card(s, 6.9, 1.2, 5.8, 5.9, 'Adjunctive / Supportive Care');
s.addText([
{ text: '• Apixaban 2.5 mg for thrombosis\n', options: { breakLine: true } },
{ text: '• PPI, calcium, vitamin D\n', options: { breakLine: true } },
{ text: '• Eye and ear supportive medications\n', options: { breakLine: true } },
{ text: '• Psychiatry: sertraline 25 mg HS, meloset 3 mg HS\n', options: { breakLine: true } },
{ text: '• Multidisciplinary specialty inputs obtained', options: {} }
], { x: 7.3, y: 1.9, w: 5.0, h: 3.8, fontSize: 14, color: C.textDark });
}
// Slide 8: Outcome and follow-up
{
const s = pptx.addSlide();
addHeader(s, 'Outcome, Follow-up, and Learning Points');
card(s, 0.6, 1.2, 6.2, 5.9, 'Early Outcome');
s.addText([
{ text: '• Clinical stabilization achieved\n', options: { breakLine: true } },
{ text: '• Respiratory status improved\n', options: { breakLine: true } },
{ text: '• Discharged on 03/04/2026 with planned rheumatology follow-up\n', options: { breakLine: true } },
{ text: '• OPD CBC (15/04/2026):\n', options: { breakLine: true } },
{ text: ' Hb 11.3, WBC 12.15, Platelets 776, ESR 38\n', options: { breakLine: true } },
{ text: ' -> trend toward improvement', options: {} }
], { x: 1.0, y: 1.9, w: 5.4, h: 4.1, fontSize: 14, color: C.textDark });
card(s, 6.9, 1.2, 5.8, 5.9, 'Teaching Messages');
s.addText([
{ text: '• Suspect ANCA vasculitis in hemoptysis + ENT features + inflammatory markers\n', options: { breakLine: true } },
{ text: '• Strong PR3 positivity can expedite diagnosis when biopsy is not feasible\n', options: { breakLine: true } },
{ text: '• Evaluate vascular complications (thrombosis) early\n', options: { breakLine: true } },
{ text: '• Multidisciplinary care improves outcomes in systemic vasculitis', options: {} }
], { x: 7.3, y: 1.9, w: 5.0, h: 4.1, fontSize: 14, color: C.textDark });
s.addText('Thank you', {
x: 11.2, y: 6.8, w: 1.6, h: 0.3, fontSize: 12, bold: true, color: C.accent, align: 'right'
});
}
pptx.writeFile({ fileName: '/home/daytona/workspace/rheumignite-gpa/output/RHEUMIGNITE_GPA_Case_Dr_Ayushi_Agrawal.pptx' });
node /home/daytona/workspace/rheumignite-gpa/src/generate_case_presentation.js && ls -la /home/daytona/workspace/rheumignite-gpa/output
RHEUMIGNITE GPA Case Dr Ayushi Agrawal
Presentation · PPTX